Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
| 适应症 | Non Alcoholic Steatohepatitis, Fibrosis |
|---|---|
| 分期 | 1/2期 |
| 申办方 | Stanford University |
| 状态 | 已完成 |
| 受试者人数 | 53 人 |
| 干预（药物） | Idebenone |
| 开始日期 | 2021年7月30日 |
| 完成日期 | 2023年7月5日 |
| 结果公布日 | 2026年3月27日 |
摘要
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
| Idebenone | 9 Participants |
|---|---|
| Placebo | 4 Participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.